EMA Authorised: Adcirca (previously Tadalafil Lilly) (tadalafil) — Eli Lilly Nederland B.V.

View source ↗

Summary

EU marketing authorisation granted for Adcirca (tadalafil) to treat pulmonary arterial hypertension; the marketing authorisation holder is Eli Lilly Nederland B…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Adcirca (tadalafil)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Eli Lilly Nederland B.V.. Decision date: 27/01/2026